FDA panel reversal: now backs Shire/Noven ADHD patch

Share this article:

An FDA panel last Friday supported an experimental skin patch for treating pediatric attention deficit hyperactivity disorder (ADHD) but discouraged its use as a first-line therapy, Dow Jones Newswires reported.
The panel said that Shire and Noven Pharmaceuticals' proposed Daytrana skin patch should contain a strong recommendation to physicians to try oral therapies first until more information is known about skin reactions.
The FDA is expected to make a decision on whether to approve the patch by year's end.
FDA medical reviewer Robert Levin had recommended that the agency reject the patch, due to concerns about weight loss and insomnia. But on Friday, in a presentation to the independent panel, Levin said the patch was worthy of approval, according to the Dow Jones report. Levin said he had obtained information suggesting most side effects of the patch were similar to those seen with some oral ADHD drugs.
The patch contains methylpheni-date, also the main component in Novartis' Ritalin.
The FDA rejected the product in 2003. To address agency concerns, Shire and Noven submitted an application this year with more information and proposing to have children wear it for nine hours instead of 12.

Share this article:

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.